RNS Number:7815R
Celsis International PLC
2 October 2000


CELSIS INTERNATIONAL PLC

Announces Supply Agreement with Medical Packaging Corporation ("MPC")

Celsis International plc, the microbial risk management group, today
announces a Supply Agreement with Medical Packaging Corporation ("MPC") for
the new Celsis snapshot device.

Medical Packaging Corporation, based in the United States, is a leading
manufacturer of medical devices for the diagnostic and clinical laboratory
industries.  MPC will supply snapshot, Celsis' new innovative hygiene
monitoring device, from its base in California.

Snapshot, due to be launched in early October, is the world's first hygiene
test to contain liquid stable bioluminescence reagent.  This novel reagent
developed by Celsis scientists in Cambridge is a major step forward in
reagent technology and gives improved performance, consistency as well as
simplifying the manufacturing processes.  The new device will provide users
with improved confidence in hygiene monitoring results, through more precise
and reliable testing in an easy-to-use format.

MPC will also work with Celsis on a program of continuous improvement to
make more user friendly and competitive sampling devices.

Peter Grant, Director of Business Development, Celsis, said:
"We are extremely pleased to be entering in to a supply agreement with MPC
for the snapshot device, and are very optimistic about our future plans
together.  The combination of Celsis' technology and MPC's manufacturing
facilities will enhance our product offering.  Together with the relaunch of
systemSURE last year, this reinforces Celsis' strategy to grow our presence
in the hygiene monitoring sector."

Enquiries:
Celsis International plc
Peter Grant, Director of Business Development          +44 (0) 1223 426 008
Jenny Parsons, Corporate Communications

Brunswick Group
Melissa Miller                                         +44 (0) 207 404 5959
Notes to Editors:

Celsis International plc
Celsis International plc specialises in the development and supply of rapid
diagnostic and monitoring systems to detect and measure microbial
contamination.  It has successfully developed a range of tests for use in
the food, beverage, pharmaceutical, cosmetic and toiletries industries.
These tests are based upon the technology of ATP Bioluminescence; such tests
detect the presence of microbial contamination by monitoring light emitted
when adenosine triphosphate ("ATP"), a naturally occurring substance present
in all living organisms, is brought into contact with luciferase, an enzyme
produced by fireflies.

Medical Packaging Corporation
MPC is both a contract and an original manufacturer of medical devices for
the in vitro diagnostic and clinical laboratory industries, located in
Camarillo, California.  Their primary capabilities include product design
and development expertise and automated manufacture.
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Celadon Pharmaceuticals Charts.
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Celadon Pharmaceuticals Charts.